← Back to Clinical Trials
Recruiting NCT04057638

NCT04057638 Craniomaxillofacial and Upper Extremity Allotransplantation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04057638
Status Recruiting
Phase
Sponsor NYU Langone Health
Condition Face Injuries
Study Type INTERVENTIONAL
Enrollment 10 participants
Start Date 2019-06-17
Primary Completion 2026-01-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 64 Years
Study Type INTERVENTIONAL
Interventions
Combined Craniomaxillofacial and Upper Extremity Allotransplantation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 10 participants in total. It began in 2019-06-17 with a primary completion date of 2026-01-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to evaluate functional and aesthetic outcomes of combined facial and upper extremity composite tissue allografts on patients who have not achieved functional and aesthetic outcomes with conventional reconstructive surgical strategies and prosthetic devices.

Eligibility Criteria

Inclusion Criteria: * Signed and dated all required Institutional Review Board (IRB) approved consent forms. * Male or female recipient between the ages of 18-64 years. Recipients do not need to be of the same sex as the donor. * Facial composite tissue defect requiring facial transplantation as determined by the treating Plastic and Reconstructive Surgeon. Inclusive facial functional subunit tissue loss. Including but not limited to irreparable peri-oral, peri-orbital, and peri-nasal damage. * Missing part of one or both hands and forearms. * Must be HIV negative at the time of transplant. * Crossmatch is negative at the time of transplant. * Patient has been encouraged to seek a second opinion from a Plastic Surgeon with specialized focus in facial reconstruction. * Patient has been encouraged to seek a second opinion from a Plastic Surgeon with specialized focus in upper extremity reconstruction. * Willingness to participate in ongoing psychiatric, psychological and social work evaluations prior to and post-transplant surgery. * The subject is able to complete pre-transplant examination and screening procedures. * Patient has been approved by Patient Selection Committee for placement on the recipient waiting list. * The subject is willing to continue immunosuppression regimen as directed by treating physician. * Subject is willing and able to return to follow-up visits as described in treatment plan. * Subjects must have autogenous tissue options available for reconstruction in event of graft failure. * Normal glomerular filtration rate (GFR) \>60. * Negative pregnancy test within 48hrs of transplant for women of childbearing age and who agree to use a reliable form of contraception for one year following transplant. Exclusion Criteria: * Uncontrolled infection or severe concomitant diseases which would exclude the recipient from transplantation * Serious co-morbidities * Positive serology for HIV; Hepatitis B Antigen * Active malignancy within 5 years with the exclusion of non-melanoma * Substance abuse disorders not currently under control (as determined by the Michigan Alcohol Screening Test - see Appendix N.1: Subjects with a score of 3 or more will be excluded) * Body Dysmorphic disorder (see Appendix N.2 for screening tool). Less severe psychiatric conditions are addressed on a case by case basis * Active Severe Psychiatric Illness * Cognitive limitations affecting the patient's ability to provide informed consent * Recent history of medical non-adherence * Unstable social situation as evidence by lack of stable housing and/or lack of a supportive significant other. * Recent history of medical non-adherence. * Lack of stable housing and/or supportive significant other/caregiver throughout all phases of the study * Currently active smoker within 1 year * Subjects with any cognitive deficits related to a traumatic brain injury (TBI) and or any organic neurological disorders * Any other psychological status that would hinder the success or safety of the transplantation. * Level of amputation proximal to mid-humerus: some presence of proximal muscles is required to motor a functioning hand. * Congenital Abnormalities: co-existent absence/atrophy/agenesis of any tissue may affect post-transplant results * History of amputation of less than six months: subject must be allowed to attempt prosthetic use prior to hand transplantation. This can be waived in cases where the recipient requires amputation/revision of the transplant site at the time of transplantation. However, if at all possible, it is highly encouraged that the patient has ruled out prosthetics as an alternative to transplantation. * Blindness: blind amputees may be poor candidates because sensory return in the hand may not provide sufficient protective sensation * Pregnancy

Contact & Investigator

Central Contact

Thomas Calahan, BA

✉ Thomas.Calahan@nyulangone.org

📞 (929) 455-5826

Principal Investigator

Eduardo Rodriguez, MD, DDS

PRINCIPAL INVESTIGATOR

NYU Langone Medical Center

Frequently Asked Questions

Who can join the NCT04057638 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 64 Years, studying Face Injuries. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04057638 currently recruiting?

Yes, NCT04057638 is actively recruiting participants. Contact the research team at Thomas.Calahan@nyulangone.org for enrollment information.

Where is the NCT04057638 trial being conducted?

This trial is being conducted at New York, United States.

Who is sponsoring the NCT04057638 clinical trial?

NCT04057638 is sponsored by NYU Langone Health. The principal investigator is Eduardo Rodriguez, MD, DDS at NYU Langone Medical Center. The trial plans to enroll 10 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology